Molecular Scores to Predict Ovarian Cancer Outcomes: A Worthy Goal, but Not Ready for Prime Time
Open Access
- 13 April 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 104 (9) , 642-645
Abstract
Ovarian carcinoma has the highest mortality of all gynecological cancers. The American Cancer Society estimates that in 2012, about 22 280 new cases of ovarian cancer will be diagnosed, and 15 500 women will die of ovarian cancer in the United States ( 1 ). Despite achieving high rates of remission following radical surgery and platinum-based chemotherapy, most women relapse and ultimately die of chemoresistant disease. Advances in chemotherapy lengthen survival for women with advanced-stage (stages III and IV) disease but have not changed the likelihood of cure. Biomarkers, such as the rate of decline of serum cancer antigen 125 (CA-125, also known as mucin-16) level or the absolute CA-125 nadir, can be predictors of progression-free and overall survivals ( 2–4 ); however, when faced with a slowly declining level of CA-125 during primary treatment, the oncologist has few effective alternatives. With almost 80% of primary ovarian cancers initially responding to platinum-based therapy, a prospective biomarker would need to be highly predictive of treatment failure because alternative treatments would be purely experimental.Keywords
This publication has 20 references indexed in Scilit:
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Functional Restoration of BRCA2 Protein by SecondaryBRCA2Mutations inBRCA2-Mutated Ovarian CarcinomaCancer Research, 2009
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical OutcomeClinical Cancer Research, 2008
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum ResistanceCancer Research, 2008
- Resistance to therapy caused by intragenic deletion in BRCA2Nature, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyGynecologic Oncology, 2007
- Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian CancersClinical Cancer Research, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian StudyGynecologic Oncology, 1995